Virtual Reality Cue Exposure for Smoking Cessation
“Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation”
The proposed study represents a crucial and important stage in translating basic research to strategies for treating nicotine dependence. The investigation addresses an important public health issue by testing an intervention - informed by basic research - that may lead to a more effective and efficient treatment for smokers. The expected findings should provide initial effect size data for the addition of isradipine to an integrated psychosocial/behavioral and pharmacological smoking cessation intervention for smokers, and thus provide the necessary data for a large-scale follow-up trial.
Drug - Isradipine
Isradipine will be administered 90 minutes prior to the initiation of cue exposure.
Behavioral - Cue Exposure
Participants will be exposed to visual smoking cues (i.e., immersive 360 degree video environments) delivered through consumer VR headset and handle cigarette packs to activate and extinguish craving.
Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation